849 related articles for article (PubMed ID: 8674006)
21. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
[TBL] [Abstract][Full Text] [Related]
22. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
[TBL] [Abstract][Full Text] [Related]
24. A weekly alternating chemotherapy regimen with low toxicity for the treatment of aggressive lymphoma.
Bower M; Brock C; Gulliford T; O'Reilly SM; Smith DB; Newlands ES
Cancer Chemother Pharmacol; 1996; 38(1):106-9. PubMed ID: 8603443
[TBL] [Abstract][Full Text] [Related]
25. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
26. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
[TBL] [Abstract][Full Text] [Related]
27. A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.
Köhne CH; Bedenne L; Carrato A; Bouché O; Popov I; Gaspà L; Valladares M; Rougier P; Gog C; Reichardt P; Wils J; Pignatti F; Biertz F
Eur J Cancer; 2013 May; 49(8):1868-75. PubMed ID: 23571150
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
[TBL] [Abstract][Full Text] [Related]
29. [Infusiontherapy with 5-fluorouracil ("infusional" 5-FU) in solid tumors].
Wilke H; Stahl M; Köster W; Vanhöfer U
Med Klin (Munich); 2000 Jun; 95 Suppl 1():3-8. PubMed ID: 10941246
[TBL] [Abstract][Full Text] [Related]
30. Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment.
Herold M; Hieke K
Value Health; 2003; 6(2):167-74. PubMed ID: 12641867
[TBL] [Abstract][Full Text] [Related]
31. Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma.
Schmitz S; Aly F; Steinmetz T; Diehl V; Rehwald U
Onkologie; 2006 Jun; 29(6):258-64. PubMed ID: 16770087
[TBL] [Abstract][Full Text] [Related]
32. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
Cocconi G; Bisagni G; Bella M; Acito L; Anastasi P; Carpi A; Di Costanzo F; Frassoldati A; Mosconi A; Borrini A; Buzzi P
Am J Clin Oncol; 1999 Dec; 22(6):593-600. PubMed ID: 10597744
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R
J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087
[TBL] [Abstract][Full Text] [Related]
34. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
[TBL] [Abstract][Full Text] [Related]
36. Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin Lymphoma.
Evans SS; Gandhi AS; Clemmons AB; DeRemer DL
J Pharm Pract; 2017 Aug; 30(4):400-405. PubMed ID: 27432462
[TBL] [Abstract][Full Text] [Related]
37. Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer.
Grem JL
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):13-9. PubMed ID: 11219972
[TBL] [Abstract][Full Text] [Related]
38. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy.
Sparano JA; Wiernik PH; Leaf A; Dutcher JP
J Clin Oncol; 1993 Jun; 11(6):1071-9. PubMed ID: 8501493
[TBL] [Abstract][Full Text] [Related]
39. Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents.
Lokich J; Anderson N
Ann Oncol; 1997 Jan; 8(1):15-25. PubMed ID: 9093703
[TBL] [Abstract][Full Text] [Related]
40. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
Fetting JH; Gray R; Fairclough DL; Smith TJ; Margolin KA; Citron ML; Grove-Conrad M; Cella D; Pandya K; Robert N; Henderson IC; Osborne CK; Abeloff MD
J Clin Oncol; 1998 Jul; 16(7):2382-91. PubMed ID: 9667255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]